2024
Mechanism of Hyperactive PLCγ1 Signaling in T-Cell Leukemia/Lymphoma
Zeng L, Zhang X, Xiong Y, Hajicek N, Sondek J, Su X. Mechanism of Hyperactive PLCγ1 Signaling in T-Cell Leukemia/Lymphoma. Blood 2024, 144: 48-48. DOI: 10.1182/blood-2024-193065.Peer-Reviewed Original ResearchHDACi resistancePeripheral T-cell lymphomaCutaneous T-cell lymphomaAdult T-cell leukemia/lymphomaLiquid-liquid phase separationT-cell lymphomaT-cell leukemia/lymphomaT cell proliferationHistone deacetylasesTotal internal reflection fluorescenceT cellsTCR signalingDrug resistanceDysregulation of LLPSWild typeMolecular mechanismsAberrant protein aggregationInhibitor resistanceResistance to HDAC inhibitorsMemory T cell developmentT cell receptor signalingActivation of T cellsPromote T cell proliferationT-cell malignanciesBcl-2 expressionGeneration and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Ren J, Liao X, Lewis J, Chang J, Qu R, Carlson K, Foss F, Girardi M. Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications 2024, 15: 519. PMID: 38225288, PMCID: PMC10789731, DOI: 10.1038/s41467-024-44786-2.Peer-Reviewed Original ResearchConceptsAntibody-dependent cellular cytotoxicityDonor T cellsT cellsAdeno-associated virus transductionHealthy donor T cellsHost-versus-graft reactivityEnhanced antibody-dependent cellular cytotoxicityCAR-T cellsGraft-versus-hostT cell killingT-cell malignanciesMalignant T cellsNormal T-cellT cell receptorOff-target toxicityPre-existing immunoreactivityCAR-TDisease relapseCellular cytotoxicityVirus transductionCurrent treatmentPersister killingFc engineeringB2MIn vivo
2023
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma
Wartewig T, Daniels J, Schulz M, Hameister E, Joshi A, Park J, Morrish E, Venkatasubramani A, Cernilogar F, van Heijster F, Hundshammer C, Schneider H, Konstantinidis F, Gabler J, Klement C, Kurniawan H, Law C, Lee Y, Choi S, Guitart J, Forne I, Giustinani J, Müschen M, Jain S, Weinstock D, Rad R, Ortonne N, Schilling F, Schotta G, Imhof A, Brenner D, Choi J, Ruland J. PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma. Nature Cancer 2023, 4: 1508-1525. PMID: 37723306, PMCID: PMC10597841, DOI: 10.1038/s43018-023-00635-7.Peer-Reviewed Original ResearchConceptsPD-1T-NHLAP-1 activityT-cell non-Hodgkin lymphomaImmune checkpoint receptor PD-1Cell non-Hodgkin lymphomaCheckpoint receptor PD-1Receptor PD-1Non-Hodgkin lymphomaT-cell lymphomaT-cell malignanciesPrimary patient samplesTractable mouse modelAdvanced diseaseInferior prognosisProtein-1 transcription factorT cellsCell lymphomaMouse modelCell malignanciesATP citrate lyase activityACLY inhibitionPatient samplesTumor suppressive mechanismKey tumor suppressor
2022
Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies
Zain, Iyer S, Sica R, Ho P, Hu B, Prica A, Weng W, Kim Y, Khodadoust, Palomba M, Foss F, Tipton K, Cullingford E, Horwitz S, Sharma A, Horwitz S. Ther-O-02 The COBALT-LYM study of CTX130: a phase 1 dose escalation study of CD70-targeted allogeneic CRISPR-Cas9–engineered CAR T cells in patients with relapsed/refractory (R/R) T-cell malignancies. European Journal Of Cancer 2022, 173: s21. DOI: 10.1016/s0959-8049(22)00591-3.Peer-Reviewed Original ResearchS262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES
Iyer S, Sica R, Ho P, Hu B, Zain J, Prica A, Weng W, Kim Y, Khodadoust M, Palomba M, Foss F, Tipton K, Cullingford E, He Q, Sharma A, Horwitz S. S262: THE COBALT‐LYM STUDY OF CTX130: A PHASE 1 DOSE ESCALATION STUDY OF CD70‐TARGETED ALLOGENEIC CRISPR‐CAS9–ENGINEERED CAR T CELLS IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) T‐CELL MALIGNANCIES. HemaSphere 2022, 6: 163-164. DOI: 10.1097/01.hs9.0000843940.96598.e2.Peer-Reviewed Original ResearchComparative Outcomes for Mature T and NK/T-cell Lymphomas in People with and without HIV and to AIDS-Defining Lymphomas
Koh MJ, Merrill MH, Koh MJ, Stuver R, Alonso CD, Foss FM, Mayor AM, Gill J, Epeldegui M, Cachay E, Thorne JE, Silverberg MJ, Horberg MA, Althoff K, Nijhawan AE, McGinnis KA, Lee JS, Rabkin CS, Napravnik S, Li J, Castilho JL, Shen C, Jain S. Comparative Outcomes for Mature T and NK/T-cell Lymphomas in People with and without HIV and to AIDS-Defining Lymphomas. Blood Advances 2022, 6: 1420-1431. PMID: 35026839, PMCID: PMC8905704, DOI: 10.1182/bloodadvances.2021006208.Peer-Reviewed Original ResearchConceptsT-cell lymphomaAnaplastic large cell lymphomaB-cell lymphomaHodgkin's lymphomaNorth American AIDS Cohort CollaborationNK/T-cell lymphomaPrimary central nervous system lymphomaModern antiretroviral therapy (ART) eraCentral nervous system lymphomaLarge B-cell lymphomaAntiretroviral therapy eraComprehensive Oncology MeasuresMature T-cell lymphomasNervous system lymphomaLarge cell lymphomaT-cell malignanciesMature T cellsCohort CollaborationTherapy eraOverall survivalSystem lymphomaHistologic confirmationLymphoma treatmentT cellsComparative outcomes
2016
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal Of Hematology & Oncology 2016, 9: 22. PMID: 26965915, PMCID: PMC4785666, DOI: 10.1186/s13045-016-0243-8.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibiotics, AntineoplasticDepsipeptidesDisease ProgressionDisease-Free SurvivalDrug Administration ScheduleDrug Resistance, NeoplasmFatigueFemaleHistone Deacetylase InhibitorsHumansLymphoma, T-Cell, PeripheralMaleMiddle AgedNauseaNeoplasm Recurrence, LocalNeutropeniaRemission InductionTime FactorsTreatment OutcomeYoung AdultConceptsPeripheral T-cell lymphomaRefractory peripheral T-cell lymphomaStable diseaseT-cell lymphomaClinical benefitPivotal trialsCell lymphomaDay 1Good responseLong stable diseaseObjective response rateProgression-free survivalUnconfirmed complete responseT-cell malignanciesHistone deacetylase inhibitorsProlonged dosingDurable responsesMedian durationObjective responsePartial responseComplete responseCurrent therapiesProtocol amendmentCell malignanciesPatients
2011
Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients
Lin WM, Lewis JM, Filler RB, Modi BG, Carlson KR, Reddy S, Thornberg A, Saksena G, Umlauf S, Oberholzer PA, Karpova M, Getz G, Mane S, Garraway LA, Dummer R, Berger CL, Edelson RL, Girardi M. Characterization of the DNA Copy-Number Genome in the Blood of Cutaneous T-Cell Lymphoma Patients. Journal Of Investigative Dermatology 2011, 132: 188-197. PMID: 21881587, PMCID: PMC3841973, DOI: 10.1038/jid.2011.254.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaBlood involvementLeukemic cutaneous T-cell lymphomaCutaneous T-cell lymphoma patientsT-cell lymphoma patientsNormal CD4 countPeripheral blood isolatesT-cell lymphomaCTCL cell linesPotential future therapeutic developmentsT-cell malignanciesFuture therapeutic developmentSignificant copy number alterationsCD4 countSpectrum of stagesCTCL patientsSézary syndromeLymph nodesLymphoma patientsHodgkin's lymphomaPeripheral bloodBlood isolatesCutaneous patchCTCL samplesPatients
2003
Peripheral T- cell lymphomas: diagnosis and management
Dearden CE, Foss FM. Peripheral T- cell lymphomas: diagnosis and management. Hematology/Oncology Clinics Of North America 2003, 17: 1351-1366. PMID: 14710889, DOI: 10.1016/s0889-8588(03)00119-9.Peer-Reviewed Original ResearchConceptsFirst-line therapyT-cell lymphomaCampath-1HResponse rateLine therapyPurine analoguesT-PLLAllogeneic bone marrow transplantationPeripheral T-cell lymphomaThird of patientsFavorable prognostic factorBone marrow transplantationMonoclonal antibody therapyStem cell transplantationNon-randomized studiesMature T-cell neoplasmsMinimal residual diseaseT-cell neoplasmsHigh response rateT-cell malignanciesLargest disease groupRisk of toxicityDurable remissionsRefractory patientsPreparative regimens
2002
Transimmunization and the evolution of extracorporeal photochemotherapy
Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfusion And Apheresis Science 2002, 26: 181-190. PMID: 12126204, DOI: 10.1016/s1473-0502(02)00011-3.Peer-Reviewed Original ResearchConceptsDC/T cell interactionExtracorporeal photopheresisT cell responsesT cell interactionsT cell receptorPotent T cell responsesSpecific T cell responsesCutaneous T-cell lymphomaT cell-mediated diseaseDendritic cell therapyT cell reactionsT-cell lymphomaOrgan transplant rejectionT-cell malignanciesExtracorporeal photochemotherapySelective immunotherapyTransplant rejectionImmune effectsImmune responsePatients' leukocytesCell malignanciesEffective antigenCell therapyFirst FDACancer cells
2001
The Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell Lymphoma
BERGER C, LONGLEY J, HANLON D, GIRARDI M, EDELSON R. The Clonotypic T Cell Receptor Is a Source of Tumor‐associated Antigens in Cutaneous T Cell Lymphoma. Annals Of The New York Academy Of Sciences 2001, 941: 106-122. PMID: 11594564, DOI: 10.1111/j.1749-6632.2001.tb03715.x.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsAntigens, NeoplasmCancer VaccinesCD8-Positive T-LymphocytesCell LineCells, CulturedHumansHybridomasImmunoglobulin IdiotypesLymphocyte ActivationLymphoma, T-Cell, CutaneousMiceNeoplasm TransplantationPeptidesReceptors, Antigen, T-CellSkin NeoplasmsSurvival RateT-Lymphocytes, CytotoxicTransfectionConceptsCutaneous T-cell lymphomaT-cell lymphomaT cell receptorClonotypic T cell receptorCell lymphomaAutologous CD8 T cellsCD8 T cell linesCell receptorBeta chainCD8 T cell recognitionImmunogenic tumor peptidesCD8 T cellsCell surface TCR expressionClass I MHC moleculesSource of tumorsT cell recognitionT-cell malignanciesTCR beta chainI MHC moleculesT cell linesTCR epitopesTumor epitopesDendritic cellsSurface TCR expressionCancer vaccines
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply